New Tumor-Injected drug shows promise in early cancer trial
NCT ID NCT06022029
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find the safest and most effective dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ONM-501 (injected into tumors) and cemiplimab (Libtayo, given intravenously)
What this could lead to
If successful, this could point toward a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The approach is experimental and may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allegheny Health Network
COMPLETEDPittsburgh, Pennsylvania, 15224, United States
-
BRCR Global
WITHDRAWNTamarac, Florida, 33321, United States
-
California Research Institute
ACTIVE_NOT_RECRUITINGLos Angeles, California, 90027, United States
-
Cancer Care Wollongong
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gabrail Cancer Center Research
COMPLETEDCanton, Ohio, 44718, United States
-
MD Anderson Cancer Center
ACTIVE_NOT_RECRUITINGHouston, Texas, 77030, United States
-
Ohio State University
COMPLETEDColumbus, Ohio, 43210, United States
-
Princess Alexandra Hospital | Metro South Health
RECRUITINGWoolloongabba, Queensland, 4102, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Southern Oncology Clinical Research Unit
COMPLETEDBedford Park, South Australia, Australia
-
St John of God Subiaco Hospital
ACTIVE_NOT_RECRUITINGSubiaco, Western Australia, 6008, Australia
-
St Vincent's Hospital
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tasman Oncology Research
RECRUITINGSouthport, Queensland, 4215, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPMC Hillman Cancer Center
COMPLETEDPittsburgh, Pennsylvania, 15232, United States
-
University of Texas Southwestern Medical Center
COMPLETEDDallas, Texas, 75390, United States
-
University of the Sunshine Coast Clinical Trials
RECRUITINGBuderim, Queensland, 4556, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Virginia Cancer Specialists, PC
COMPLETEDFairfax, Virginia, 22031, United States